Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. [electronic resource]
Producer: 20071105Description: 213-8 p. digitalISSN:- 0301-4800
- Alanine Transaminase -- blood
- Antiviral Agents -- therapeutic use
- Ascorbic Acid -- administration & dosage
- Carnosine -- administration & dosage
- Dietary Supplements
- Drug Therapy, Combination
- Fatty Acids, Unsaturated -- metabolism
- Female
- Flow Cytometry
- Hepatitis C, Chronic -- drug therapy
- Humans
- Interferon alpha-2
- Interferon-alpha -- therapeutic use
- Male
- Middle Aged
- Organometallic Compounds -- administration & dosage
- Polyethylene Glycols
- Recombinant Proteins
- Ribavirin -- therapeutic use
- Thiobarbituric Acid Reactive Substances -- metabolism
- Time Factors
- Transaminases -- blood
- Treatment Outcome
- Vitamin E -- administration & dosage
- Vitamins -- administration & dosage
- Zinc -- administration & dosage
- Zinc Compounds -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.